Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
NCT00226954Phase 2Terminated
- Sponsor
- Stanford University
- Start
- Mar 2003
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zoledronic acid in prostate cancer (PCa), sponsored by Stanford University. Started Mar 2003; status: terminated.
02
Drugs
zoledronic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00226954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00226954.